Specialty medications are high-cost and generally not available in generic forms. Manufacturers always have specific programs to assist providers and patients to use their specialty drugs. By joining those programs, patients are required to sign authorization forms that allow PHI to be released by SP to manufacturers. Different manufacturers have divergent authorization forms while HIPAA and many states have their own requirements and information on the forms. It is a challenge for manufacturers to create authorization forms that can meet states’ demand. Therefore, using original authorization forms created by manufacturers might violate either HIPAA or state laws, where SPs are located at. SPs need to have their own compliance team to handle authorizations. The article lists two options that SPs can choose to proceed with authorization forms. The first option is SPs can …show more content…
This step will help SPs to prevent violation when releasing PHI to external parties. Also, SPs need to have a system that can track if the authorizations are signed, dated, and in place for each patients. This process will ensure that SPs can properly disclose PHI to manufacturers. Sharing patients’ information with manufacturers play very important part in optimizing patients’ health outcomes while on specialty medications. The information will help researchers have further understanding about side effects and mechanism of actions, which were not observed in clinical trial phases. Patients’ authorizations are the keys of disclosing PHI to manufacturers. Therefore, HIM professionals’ roles are to ensure that authorization forms signed by patients must meet HIPAA and state regulations as well as manufacturers’ criteria of collected information. The HIPAA rules have six core requirements on PHI authorization
. HIPAA privacy rules are complicated and extensive, and set forth guidelines to be followed by health care providers and other covered entities such as insurance carriers and by consumers. HIPAA is very specific in its requirements regarding the release of information, but is not as specific when it comes to the manner in which training and policies are developed and delivered within the health care industry. This paper will discuss how HIPAA affects a patient's access to their medical records, how and under what circumstances personal health information can be released to other entities for purposes not related to health care, the requirements regarding written privacy policies for covered entities, the training requirements for medical office employees and the consequences for not following the policy.
Pharmacy is highly regulated and must of the data is already in electronic form, data review is much easier. Reviewing the drugs that are being administered and possibly steering usage away from high cost brand drugs to lower cost generic drugs can lead to a reduction in costs without a decrease in health outcome. Simply stated, health outcomes are improved when a healthcare provider has a complete access to all records for the patient and when those records are enhanced with information such as drug interactions and dosing calculation among other things, patient safety can also be improved (AHA,
...vacy screen on the computer and/or turning the computer away so customers cannot see what’s on the screen, and use a secure network to receive new prescriptions or request refills. A patient must be notified and give authorization to allow a list of their drugs be given to a marketing company. The authorization must say what the data disclosure and use is being planned for and the date when the authorization will expire. In a community practice a pharmacist cannot discuss treatment with anyone unless patient signs authorization. In an institutional practice the patient can call the pharmacist and give permission to talk to a doctor if able to speak. In case of an emergency, such as a heart attack or car accident, the doctor can call the pharmacist to get the information without patient consent. A patient must give a written authorization in a community pharmacy.
When doctors prescribe medication for their patients, a local retail pharmacy is most likely to be utilized to fill the order. However, there is a growing population of older Americans that are no longer able to live independently and must reside in nursing homes or assisted living facilities. In order for this vulnerable population to receive their medications, a different kind of pharmacy is needed, these are known as LTC, long term care pharmacies. Within these specialized pharmacies there are highly trained employees called CPhTs, certified pharmacy technicians who are overseen by state licensed RPHs, otherwise known as pharmacists.
Protecting patient information is an important task for any health care provider. The Heath Insurance Portability and Accountability Act (HIPAA), also known as the Standards for Privacy of Individually Identifiable Health Information, was approved by the United States Congress in 1996. It was the first act to provide national regulations for the use of patient health information. This privacy rule outlines the boundaries for the use of personal health information, including specific guidelines to ensure HIPAA-compliance. In order to market under HIPAA, there are certain privacy rules in place to protect patients. According to HIPAA, marketing is defined as “a communication about a product or service that encourages recipients to purchase or use the product or service”2. This definition can include any type of marketing communication. Marketing also includes when a covered entity is paid by a third party for patient health information that they can use for their own purposes. It also covers cases of an associate communicating and encouraging patients to buy or use their product or service.
Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule, NIH Publication Number 03-5388. Retrieved November 12, 2011 from http://privacyruleandresearch.nih.gov/pr_02.asp
Office, U. A. (2002). Prescription drugs: FDA oversight of direct-to-consumeradvertising has limitations (GAO-3-177). Washington, D.C.
Before a person is prescribed this pill, the patient is supposed to undergo a complete physical examination, the patients record should be contained with detailed documentation of the nature and intensity of the pain, current and past treatment, other illnesses, and their history of drug and alcohol use.
Wright, A., FebloWitz, J., Phansalkar, S., Liu, J., Wilcox, A., Keohane, C., … Bates, D. (2012). Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools. American Journal of Health-System Pharmacy, 69, 221-227.
The guidance explains and clarifies key provisions of the medical privacy regulation, which was published last December (HIPAA, 1996). Guaranteeing the accuracy, security, and protection of the privacy of all medical information is crucial and an ongoing challenge for many organizations. References American Medical Association (2005). Retrieved December 7, 2008, from http://www.ad http://www.ama-assn.org/.
While the HIPAA regulations call for the medical industry to reexamine how it protects patient information, the standards put in place by HIPAA do not provide ...
both the benefit and risk of all medication before approval.. In addition, FDA makes the labeling
Bar-code-assisted medication administration (BCMA) has replaced the traditional paper-based medication administration (PBMA) systems in some health care facilities. The BCMA system’s objective is to verify the five rights of medication administration meaning that “the right patient receives the right dose of the right drug by the right route at the right time (Grissinger).” The process begins with the pharmacy ensuring that all medicines are labeled correctly and that all medicines have appropriate bar codes that identify the name, dose, and form of the medication. Patient...
The aims of the post-marketing safety surveillances program are to examine and quantify new drug safety issues, to recognize risk factors of product marketing, and to control medication use patterns (3). If undesirable effects are noticed In this forth phase of trial, the drug might get withdrawn from the market.